Viewing Study NCT05945732

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:57 PM
Ignite Modification Date: 2026-05-20 @ 3:18 PM
Study NCT ID: NCT05945732
Status: RECRUITING
Last Update Posted: 2025-12-11
First Post: 2023-07-06
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: DESTINY Breast Respond HER2-low Europe
Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Unresectable Breast Cancer View
None Metastatic Breast Cancer View
None HER2-low Expressing Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Unresectable Breast Cancer View
None Metastatic Breast Cancer View
None HER2-low Expressing Breast Cancer View
None Trastuzumab Deruxtecan View
None Enhertu® View